Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Sorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 4/20 | 1.00 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 3/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 3/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 3/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL8218 | 1.00 | RAF1 (1.00) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL14739751 | 1.00 | RAF1 (1.00) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL28894639 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL18863920 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1533981 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1896610 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1533982 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1533976 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL28817561 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL27786861 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2359 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074048-A | Methods of treating cancer | 诺华股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-3750530-B1 | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER | TYRNOVO LTD (IL) | 2025-12-24 | — | — | EP | claimed |
| US-20250281624-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-09-11 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| CN-120076809-A | Combination therapy of CDK7 inhibitors with other anti-cancer therapies | 奎利恩特有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-113993898-B | RET-binding human antibodies and methods of use thereof | 瑞泽恩制药公司 | 2025-05-27 | — | — | CN | claimed |
| CN-119700702-B | PH-sensitive bionic drug lipid vesicle and preparation method and application thereof | 浙江大学医学院附属第一医院(浙江省第一医院) | 2025-05-16 | — | — | CN | claimed |
| US-20250134837-A1 | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER | TYRNOVO LTD. (IL) | 2025-05-01 | — | — | US | claimed |
| CN-119700702-A | PH-sensitive bionic drug lipid vesicle and preparation method and application thereof | 浙江大学医学院附属第一医院(浙江省第一医院) | 2025-03-28 | — | — | CN | claimed |
| WO-2022087763-A1 | COCRYSTAL CONTAINING SORAFENIB FREE BASE AND 5-FLUOROURACIL, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | 愈磐生物科技（苏州）有限公司 | 2022-05-05 | — | — | WO | claimed |
| WO-2022087371-A1 | NOVEL BICYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| WO-2022087375-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | claimed |
| US-11286469-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-03-29 | — | — | US | claimed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2022038038-A2 | MEANS FOR THE THERAPY OF TUMOR DISEASES | EPO EXPERIMENTELLE PHARMAKOLOGIE & ONKOLOGIE BERLIN-BUCH GMBH (DE) | 2022-02-24 | — | — | WO | claimed |
| EP-3953390-A1 | HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| CN-114007671-A | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancer of epithelial tissue | 休斯敦大学体系 | 2022-02-01 | — | — | CN | claimed |
| CN-113993898-A | Human antibodies that bind RET and methods of use thereof | 瑞泽恩制药公司 | 2022-01-28 | — | — | CN | claimed |